 | |
| Company type | Public |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1978; 47 years ago (1978) Jordan |
| Founder | Samih Darwazah  |
| Headquarters | London, England, UK |
Key people | |
| Products | Amoclan Prograf Suprax |
| Revenue |  US$3,156 million (2024)[1] |
| US$719 million (2024)[1] | |
| US$362 million (2024)[1] | |
Number of employees | 8,800 (2024)[2] |
| Website | www |
Hikma Pharmaceuticals plc is a Britishmultinationalpharmaceutical company with headquarters in London, UK that manufactures non-brandedgeneric and in-licensedpharmaceutical products. It was founded bySamih Darwazah inAmman,Jordan in 1978. It is listed on theLondon Stock Exchange and is a constituent of theFTSE 100 Index.
The company was founded in 1978 bySamih Darwazah inAmman, Jordan.[3] In August 1996 it became the first Arab company to export pharmaceutical products to the United States.[4] It was first listed on theLondon Stock Exchange in 2005.[3] Acquisitions in the mid-2000s include Instituto Biochimico Pavese Pharma in Italy in 2005[5] and Jazeera Pharmaceutical Industries inSaudi Arabia in 2006.[3] In 2007 the company went on to buy APM inJordan,[6] Alkan Pharma inEgypt, APM and Al Jazeera Pharma in Saudi Arabia,[6] Thymoorgan in Germany,[3] and Ribosepharm in Germany.[3] It started to acquireBaxter Healthcare Corporation's US generic injectables business, Multi-Source Injectables or MSI, and completed the transaction in May 2011.[7]
In October 2011, Hikma Pharmaceuticals entered the Moroccan market through the acquisition of Promopharm, the ninth largest pharmaceutical manufacturer in Morocco.[8] Hikma also inaugurated the Al Dar Al Arabia Pharmaceutical Manufacturing Company in Algeria in 2011. The Algerian pharmaceutical company is Hikma's second venture in Algeria after Hikma Pharma Algeria.[9]
In 2011 the company won the ICSA / Hermes Transparency in Governance Award for the best audit disclosure for aFTSE 250 company.[10]
Hikma expanded its existing presence in the Egyptian market through the acquisition of the Egyptian Company for Pharmaceuticals and Chemical Industries (EPCI) in 2012.[11] In September 2013, Hikma announced expansion into Sub-Saharan Africa with a 50:50 joint venture agreement withMIDROC Pharmaceuticals Limited, to enter the Ethiopian pharmaceutical market.[12]
On 28 May 2014, Hikma Pharmaceuticals agreed to acquire assets from the U.S. generic injectable drugs business of Germany'sBoehringer Ingelheim for up to $300 million, boosting its presence in the injected medicine market.[13]
In June 2020, Boehringer announced it would sell off part of its stake in London-listed Hikma Pharmaceuticals (28 million out of a 40 million share holding) for around $800 million.[14]
Hikma Pharmaceutical's operations span 29 manufacturing plants in 10 countries: United States,Portugal,Italy,Jordan,Saudi Arabia,Algeria,Germany,Egypt,Morocco, andTunisia.[15]
Hikma's branded business segment comprises the development and sales of branded generics and in-licensed patented products in theMENA region. Hikma has 499 products in 1,256 dosage strengths. Top products include Actos, Amoclan,Blopress, Omnicef,Prograf, andSuprax.[16]
Hikma sells specialized injectable products in the US, Europe and MENA includingargatroban,fentanyl,phenylephrine,robaxin, and iron gluconate. The company sells 200 products in 379 dosage forms and strengths.[16]
Hikma's oral generic products are sold in the US and include such products asamoxicillin,cephalexin,doxycycline,methocarbamol, andprednisone.[16]
|
